{"filing":{"accession_number":"0001213900-26-098403","cik":"0001795091","ticker":"OSTX","company_name":"OS Therapies Inc","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ea0305001-8k_ostherapies.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026098403/ea0305001-8k_ostherapies.htm"},"events":[{"id":32362,"run_id":29730,"accession_number":"0001213900-26-098403","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"OS Therapies held its 2026 Annual Meeting on September 9, 2026, at which shareholders voted on and approved three matters: election of six directors (Paul A. Romness, John Ciccio, Craig Eagle, Avril McKean Dieser, Olivier R. Jarry, and Theodore F. Search), approval of the Amended and Restated 2023 Incentive Compensation Plan, and ratification of MaloneBailey, LLP as independent auditor. All three proposals passed with majority support.","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35521,"accession_number":"0001213900-26-098403","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the Company's 2023 Incentive Compensation Plan at the 2026 annual meeting. This is a compensatory arrangement disclosure under Item 5.02(e), involving a material plan amendment that affects equity grants and performance awards for officers and directors. The filing explicitly references the proxy statement's detailed discussion of the plan's material terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:22:30.202044+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35522,"accession_number":"0001213900-26-098403","item_number":"5.07","item_title":"Submission of Matters to a Vote","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of OS Therapies' Annual Meeting held on September 9, 2026. The filing presents detailed voting tallies for three matters: election of six directors (Paul A. Romness, John Ciccio, Craig Eagle, Avril McKean Dieser, Olivier R. Jarry, and Theodore F. Search), approval of the Amended and Restated Plan, and ratification of MaloneBailey, LLP as independent auditor. All three proposals passed with majority support. This is a material governance event affecting investor understanding of board composition and shareholder-approved equity and audit arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:22:30.202044+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35521,"accession_number":"0001213900-26-098403","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the Company's 2023 Incentive Compensation Plan at the 2026 annual meeting. This is a compensatory arrangement disclosure under Item 5.02(e), involving a material plan amendment that affects equity grants and performance awards for officers and directors. The filing explicitly references the proxy statement's detailed discussion of the plan's material terms.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:22:30.202044+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-09-09"},{"id":35522,"accession_number":"0001213900-26-098403","item_number":"5.07","item_title":"Submission of Matters to a Vote","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of OS Therapies' Annual Meeting held on September 9, 2026. The filing presents detailed voting tallies for three matters: election of six directors (Paul A. Romness, John Ciccio, Craig Eagle, Avril McKean Dieser, Olivier R. Jarry, and Theodore F. Search), approval of the Amended and Restated Plan, and ratification of MaloneBailey, LLP as independent auditor. All three proposals passed with majority support. This is a material governance event affecting investor understanding of board composition and shareholder-approved equity and audit arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:22:30.202044+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-09-09"}]}